Blood pressure-independent effects of enhanced NO/cGMP signalling and gender on aortic remodelling in experimental renal hypertension by Grosz, Bianca et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
BMC Pharmacology
Open Access Poster presentation
Blood pressure-independent effects of enhanced NO/cGMP 
signalling and gender on aortic remodelling in experimental renal 
hypertension
Bianca Grosz, Stephanie Krämer, Tanja Loof, Hans H Neumayer, 
Yingrui Wang-Rosenke and Harm Peters*
Address: Department of Nephrology and Center for Cardiovascular Research, Charité-Universitätsmedizin, Berlin, Germany
Email: Harm Peters* - harm.peters@charite.de
* Corresponding author    
Background
The most important comorbidity in renal patients is rep-
resented by cardiovascular complications, with impaired
NO production as key pathway. In premenopause, estro-
gens seem to exert protective effects on the vascular sys-
tem. This study investigates the effects of both gender and
enhanced NO/cGMP signalling on aortic remodelling in
experimental hypertensive nephropathy.
Methods
Age-matched male (M) and female (F) Wistar rats were
assigned for 18 weeks into the following groups: 1) subto-
tally nephrectomized (SNX); 2) SNX Bay 41-8543-treated;
3) SNX hydralazine-treated and 4) sham operated. Bay
41-8543 is a NO-independent stimulator of soluble guan-
ylate cyclase.
Results
SNX led to increases in systolic blood pressure, with lower
levels in F rats (F-SNX 129 ± 13 mmHg vs. M-SNX 140 ±
11 mmHg). Bay 41-8543 and hydralazine reduced blood
pressure to control levels. Aortic remodelling was charac-
terized by marked media thickening in both SNX groups,
with a more pronounced increase in M versus F (127 ± 9
vs. 108 ± 6% of control; p < 0.001). Intima-media ratio
was reduced in both uremic groups, with significant sex
differences (M-SNX 66 ± 7% vs. F-SNX 80 ± 8% of control;
p < 0.01). Furthermore, gender differences were observed
in media-to-lumen ratio as indicator of aortic hypertro-
phy. The ratio was significantly higher in SNX males only
(M-SNX 131 ± 9% vs. F-SNX 107 ± 15% of control; p <
0.001). Bay 41-8543 significantly ameliorated media
thickness (111 ± 10 vs. 127 ± 9% of control in M; 101 ± 7
vs. 108 ± 6% of control in F; p < 0.05), intima-media ratio
(85 ± 10 vs. 66 ± 7% of control in M; 91 ± 6 vs. 80 ± 8%
of control in F, p < 0.01) and media-to-lumen ratio (107
± 9 vs. 131 ± 9% of control in M; p < 0.001). Despite a
similar reduction in blood pressure, hydralazine treat-
ment did not alter aortic wall remodelling. These mor-
phological changes were accompanied by elevated
collagen I and reduced elastin protein expression at the
level of aortic media, with decreased elastin/collagen ratio
in untreated SNX groups, as marker of aortic wall stiffen-
ing. Bay 41-8543 treatment successfully prevented these
molecular alterations (collagen I protein expression: 9.4 ±
0.3 vs. 14.5 ± 1.1% in females and 9.6 ± 0.4 vs. 16.1 ±
1.0% in males), while hydralazine showed no effects. SNX
was characterized by increased extracellular matrix turno-
ver with up-regulation of MMP2 and TIMP1 genes, more
pronounced in males than in females (M-SNX 1.8 ± 0.1 vs.
F-SNX 1.1 ± 0.1 for MMP2; M-SNX 4.2 ± 0.8 vs. F-SNX 2.7
± 0.6 for TIMP1; both expressed as relative values vs. con-
trols). In the male Bay 41-8543-treated group, expression
of these genes was significantly lower (1.4 ± 0.1 MMP2-
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relative expression and 1.8 ± 0.4 TIMP1-relative expres-
sion, p < 0.05).
Conclusion
The present study shows that in a model with hyperten-
sion and impaired renal function 1) aortic hypertrophy
and remodelling is significantly more severe in male gen-
der and 2) enhancing NO/GMP signalling by Bay 41-8543
ameliorates aortic wall changes significantly and in a
blood pressure-independent manner.